Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
Mesoblast (NASDAQ:MESO) has secured an option to issue up to US$50 million in convertible notes through agreements with SurgCenter principals and existing shareholders. The 5-year convertible notes, available in US$10 million tranches, feature a 5% annual coupon and can be converted to shares at US$16.25 per ADR, representing a 126% premium to Nasdaq's closing price.
The funding, subject to shareholder approval at the upcoming AGM, will be used to repay secured lenders and support working capital needs. As part of the agreement, investors will receive a US$100,000 commitment fee and warrants for up to 5 million ordinary shares, with 2 million granted upon agreement and 3 million if Mesoblast exercises the option.
Mesoblast (NASDAQ:MESO) ha ottenuto un'opzione per emettere fino a US$50 milioni in cambiali convertibili tramite accordi con i principali soggetti di SurgCenter e azionisti esistenti. Le cambiali convertibili a 5 anni, disponibili in tranche da US$10 milioni, prevedono una cedola annua del 5% e possono essere convertite in azioni a US$16,25 per ADR, pari a un premio del 126% rispetto al prezzo di chiusura del Nasdaq.
I fondi, soggetti all'approvazione degli azionisti nella prossima assemblea, saranno utilizzati per rimborsare i finanziatori garantiti e sostenere il capitale circolante. Nell'ambito dell'accordo gli investitori riceveranno una commissione di impegno di US$100.000 e warrant per un massimo di 5 milioni di azioni ordinarie: 2 milioni saranno concessi al momento dell'accordo e 3 milioni se Mesoblast eserciterà l'opzione.
Mesoblast (NASDAQ:MESO) ha asegurado una opción para emitir hasta US$50 millones en notas convertibles mediante acuerdos con los principales de SurgCenter y accionistas existentes. Las notas convertibles a 5 años, disponibles en tramos de US$10 millones, cuentan con un cupón anual del 5% y pueden convertirse en acciones a US$16,25 por ADR, lo que supone una prima del 126% respecto al cierre del Nasdaq.
Los fondos, sujetos a la aprobación de los accionistas en la próxima junta general, se destinarán a reembolsar a los prestamistas garantizados y a respaldar las necesidades de capital de trabajo. Como parte del acuerdo, los inversores recibirán una tarifa de compromiso de US$100.000 y warrants por hasta 5 millones de acciones ordinarias: 2 millones se otorgarán al firmarse el acuerdo y 3 millones si Mesoblast ejerce la opción.
Mesoblast (NASDAQ:MESO)는 SurgCenter 주요 관계자 및 기존 주주와의 계약을 통해 최대 5,000만 달러(미화) 규모의 전환사채 발행 옵션을 확보했습니다. 5년 만기의 전환사채는 1,000만 달러 단위로 제공되며 연 5%의 쿠폰이 적용되고, ADR당 16.25달러에 주식으로 전환할 수 있어 나스닥 종가 대비 126%의 프리미엄을 의미합니다.
자금은 다가오는 총회에서 주주 승인 대상이며 담보 대출 상환 및 운전자본 지원에 사용될 예정입니다. 계약의 일환으로 투자자들은 10만 달러의 약정 수수료와 최대 500만 보통주에 해당하는 워런트를 받게 됩니다. 계약 시 200만 주가 부여되며 Mesoblast가 옵션을 행사할 경우 추가로 300만 주가 부여됩니다.
Mesoblast (NASDAQ:MESO) s'est assuré une option d'émettre jusqu'à 50 millions de dollars US en billets convertibles via des accords avec les principaux acteurs de SurgCenter et des actionnaires existants. Les billets convertibles sur 5 ans, disponibles par tranches de 10 millions de dollars US, offrent un coupon annuel de 5% et peuvent être convertis en actions à 16,25 $US par ADR, soit une prime de 126% par rapport au cours de clôture du Nasdaq.
Le financement, soumis à l'approbation des actionnaires lors de la prochaine assemblée générale, sera utilisé pour rembourser les prêteurs garantis et soutenir les besoins en fonds de roulement. Dans le cadre de l'accord, les investisseurs recevront des frais d'engagement de 100 000 $US et des warrants portant sur jusqu'à 5 millions d'actions ordinaires : 2 millions seront attribués à la signature de l'accord et 3 millions supplémentaires si Mesoblast exerce l'option.
Mesoblast (NASDAQ:MESO) hat eine Option zum Emittieren von bis zu US$50 Millionen an Wandelanleihen über Vereinbarungen mit den führenden Personen von SurgCenter und bestehenden Aktionären gesichert. Die 5-jährigen Wandelanleihen, verfügbar in US$10-Millionen-Tranchen, weisen eine jährliche Verzinsung von 5% auf und können zu US$16,25 pro ADR in Aktien umgewandelt werden, was einem Aufschlag von 126% gegenüber dem Schlusskurs der Nasdaq entspricht.
Die Finanzierung, die der Zustimmung der Aktionäre auf der bevorstehenden Hauptversammlung bedarf, wird zur Rückzahlung besicherter Kreditgeber und zur Unterstützung des Betriebskapitals verwendet. Im Rahmen der Vereinbarung erhalten die Investoren eine Commitment-Gebühr von US$100.000 und Optionsscheine für bis zu 5 Millionen Stammaktien; 2 Millionen werden bei Abschluss der Vereinbarung gewährt und weitere 3 Millionen, falls Mesoblast die Option ausübt.
- None.
- 5% annual coupon represents additional interest expense
- Potential dilution for existing shareholders upon conversion
- Issuance of up to 5 million warrants could further dilute shareholders
- Requires shareholder approval at upcoming AGM
Insights
Mesoblast secures flexible financing option via $50M convertible notes at favorable terms, strengthening its capital structure while minimizing immediate dilution.
Mesoblast has strategically secured an optional financing facility of up to
The structure offers several advantages over traditional debt or equity financing. The 5-year maturity provides extended runway, while the
This facility appears primarily designed to refinance existing secured debt and enhance working capital. The option to convert to equity rather than requiring cash repayment reduces financial pressure on Mesoblast. However, if fully utilized and converted, it would result in approximately 3.08 million new ADRs, representing potential dilution.
The modest commitment fee of
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck (“Investors”) to issue, at its sole discretion, up to US
Mesoblast Chief Executive Silviu Itescu said: “We appreciate the ongoing support from our major shareholders in ensuring that the Company can optimize its capital structure and support our ongoing pipeline growth opportunities.”
Key terms of the Convertible Notes
Mesoblast at its sole discretion, subject to shareholder approval at the upcoming Annual General Meeting (AGM), may issue up to US
At any time up to the maturity date, the Investors may elect to convert the notes issued into fully paid ordinary shares or ADRs of Mesoblast at the conversion price of US
As consideration, the Investors collectively will receive a commitment fee of US
The conversion price is subject to adjustment mechanisms in the event of future share issues, capital reductions, share consolidations and other corporate actions in accordance with customary adjustment rules.
1 Using an exchange rate of 1A$:0.65US$.
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s Ryoncil® for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | |
| Paul Hughes | |
| T: +61 3 9639 6036 | |
| Media – Global | |
| Allison Worldwide | |
| Emma Neal | |
| T: +1 603 545 4843 | |
| E: emma.neal@allisonworldwide.com | |
| Media – Australia | |
| BlueDot Media | |
| Steve Dabkowski | |
| T: +61 419 880 486 | |
| E: steve@bluedot.net.au |
FAQ
What is the size and purpose of Mesoblast's (MESO) convertible note offering?
What is the conversion price for MESO's convertible notes?
What are the key terms of MESO's convertible notes?
Who are the investors in MESO's convertible note offering?
When will MESO's convertible note offering be finalized?
